TFX vs. PODD, GMED, BAX, RMD, PEN, SWAV, INSP, GKOS, MMSI, and HAE
Should you be buying Teleflex stock or one of its competitors? The main competitors of Teleflex include Insulet (PODD), Globus Medical (GMED), Baxter International (BAX), ResMed (RMD), Penumbra (PEN), Shockwave Medical (SWAV), Inspire Medical Systems (INSP), Glaukos (GKOS), Merit Medical Systems (MMSI), and Haemonetics (HAE). These companies are all part of the "surgical & medical instruments" industry.
Teleflex (NYSE:TFX) and Insulet (NASDAQ:PODD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.
Insulet has a net margin of 12.16% compared to Teleflex's net margin of 11.98%. Insulet's return on equity of 32.19% beat Teleflex's return on equity.
Insulet received 190 more outperform votes than Teleflex when rated by MarketBeat users. Likewise, 65.98% of users gave Insulet an outperform vote while only 59.68% of users gave Teleflex an outperform vote.
95.6% of Teleflex shares are held by institutional investors. 1.4% of Teleflex shares are held by company insiders. Comparatively, 0.9% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Teleflex has higher revenue and earnings than Insulet. Teleflex is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.
In the previous week, Teleflex had 1 more articles in the media than Insulet. MarketBeat recorded 6 mentions for Teleflex and 5 mentions for Insulet. Insulet's average media sentiment score of 1.27 beat Teleflex's score of 1.00 indicating that Insulet is being referred to more favorably in the news media.
Teleflex currently has a consensus target price of $267.50, suggesting a potential upside of 29.41%. Insulet has a consensus target price of $243.21, suggesting a potential upside of 46.35%. Given Insulet's stronger consensus rating and higher probable upside, analysts plainly believe Insulet is more favorable than Teleflex.
Teleflex has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Insulet has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.
Summary
Insulet beats Teleflex on 10 of the 18 factors compared between the two stocks.
Get Teleflex News Delivered to You Automatically
Sign up to receive the latest news and ratings for TFX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Teleflex Competitors List
Related Companies and Tools
